Week of October 23rd, 2020 | Vol. 9, Issue 43
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Montage
Strategic Advisory | Generic Pharma + CDMO | Exploring full range of transaction alternatives

Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization

Project Bulldog
Sell-side | Pharma Services| Life sciences consulting firm

Project Olympus
Sell-side | Pharma | Portfolio of generic injectable products
As new COVID-19 cases spike in the U.S., and ahead of an expected winter surge, the FDA just issued its first full approval for a drug to treat the disease—Gilead Sciences’ Veklury, formerly known as remdesivir. But the approval closely follows a large trial that showed no benefit for the therapy, and experts quickly questioned the FDA's move.

Veklury won approval to treat COVID-19 requiring hospitalization in adults and children 12 and older. Simultaneously, the FDA issued a new emergency use authorization for certain patients under 12. The agency approved the med based on late-stage trials showing Veklury is associated with an improved time to recovery and reduced disease progression in hospitalized patients, Gilead said.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
13 transactions totaling $736 million
Supplies, Equipment & Services
23 transactions totaling $87 million
Healthcare IT & Managed Care
8 transactions totaling $10 million
Healthcare Facilities & Distributors
19 transactions totaling $25 million
Pharma & Biotech
28 transactions totaling $722 million
Supplies, Equipment & Services
19 transactions totaling $331 million
Healthcare IT & Managed Care
9 transactions totaling $103 million
Healthcare Facilities & Distributors
1 transaction
Pharma & Biotech
33 transactions totaling $1,308 million
Supplies, Equipment & Services
8 transactions totaling $928 million
Healthcare IT & Managed Care
5 transactions totaling $421 million
Healthcare Facilities & Distributors
1 transaction totaling $25 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
October 23, 2020 - Fierce Biotech
After posting positive results from a midstage test for its RNAi candidate back in the spring, Sirnaomics has grabbed a $105 million series D round. The cash boost, co-led by existing investor Rotating Boulder Fund, new investor Walvax Biotechnology Co. Ltd. and Sunshine Riverhead Capital, will go toward the biotech seeking to push deeper into the clinic and one day follow rival and RNA pioneer Alnylam to regulatory approval.

October 22, 2020 - Fierce Pharma
When CDMO Lonza shelled out $5.5 billion for capsule maker Capsugel in 2017, it made a big bet the booming capsule market would drive revenue. Now, with demand continuing to grow, Lonza is putting another down payment on capsules to keep up. Lonza will spend $93 million to expand its capsule manufacturing by 15% across eight sites globally in a move to add more than 30 billion doses per year to its capacity, the Swiss manufacturer said Thursday.

October 22, 2020 - Contract Pharma
Catalent and BrainStorm Cell Therapeutics Inc., a developer of cell therapies for neurodegenerative diseases, entered an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS).

October 19, 2020 - Fierce Pharma
Sanofi is in the middle of an ambitious reorganization, spearheaded by CEO Paul Hudson, to slash expenses and pivot toward blockbuster Dupixent. Now, the company is reportedly mulling an asset sale that could net a few hundred million and streamline operations further.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.